AOTMiT: Transparency Council will look into robotics, prevention and myeloma, among others

Agenda:

1. Preparation of a position paper on the qualification of the healthcare benefit:
   "Robotic surgery of the thorax (lung and other thoracic cancers)"
   for the indication: D38 - Tumors of uncertain or unknown nature of the middle ear, respiratory organs and thorax.
2. Preparation of a position paper on the evaluation of the drug Elmiron (sodium pentosulfate polysulfate)
   under the drug program:
   "Treatment of painful bladder syndrome with glomerulations or Hunner's lesions, interstitial cystitis" (ICD-10: N30.1).
3. Preparation of a position paper on the evaluation of the drug Abecma (idecabtagenum vicleucelum)
   under the drug program:
   B.54 - Treatment of patients with plasmocytic myeloma (ICD-10: C90.0).
4. Preparation of a position paper on the evaluation of the foodstuff for special dietary use Staloral 300
   (mixtures of allergen extracts)
   for the indication: treatment of children aged 5-11 years with moderate or severe allergic rhinitis caused by house dust, persisting despite the use of medications to relieve symptoms, with a confirmed diagnosis on the basis of clinical history and positive allergic tests (spot skin tests or specific IgE).
5. Preparation of a position paper on the evaluation of the drug Breyanzi (lisocabtagene maraleucel)
   under the drug program:
   B.12.FM - Treatment of patients with B-cell lymphomas (ICD-10: C82, C83, C85).
6. Preparation of an opinion on the active substances nivolumab + ipilimumab
   under the drug program:
   B.59 - Treatment of patients with melanoma of the skin or mucous membranes (ICD-10: C43)
   - for off-label indications.
7. Preparation of an opinion on the active substance entecavirum
   within the framework of the drug program:
   B.106 - Prophylaxis of hepatitis B reactivation
   in post-transplant recipients or those receiving treatment related to the risk of HBV reactivation.
8. Preparation of an opinion on the active substance tenofovirum disoproxilum
   within the framework of the drug program:
   B.106 - Prophylaxis of hepatitis B reactivation
   in recipients after transplants or receiving treatment related to the risk of HBV reactivation.